Lifeway Foods slides near 52-week low after Q4 earnings miss
Probiotic maker delivers record full-year sales but quarterly disappointment overshadows margin expansion and growth outlook
Lifeway Foods shares fell nearly 1% on Tuesday, hovering just above the company's 52-week low, after the probiotic beverage maker reported fourth-quarter earnings that missed analyst expectations despite delivering record full-year sales.
The Morton Grove, Illinois-based company posted adjusted earnings per share of 16 cents for the quarter, missing the consensus estimate of 28 cents by 42.9%. Revenue of $55.4 million edged past expectations by 0.7%, providing little cushion for the earnings shortfall.
The quarterly disappointment stands in sharp contrast to the company's full-year performance. Fiscal 2025 net sales reached a record $212.5 million, up 13.7% year-over-year and 19% on a comparable basis. Net income jumped 54% to $13.9 million, while gross margins expanded by 140 basis points, according to the company's 8-K regulatory filing.
The stock is now trading at $20.71, just 9 cents above its 52-week low of $20.80 and down roughly 40% from its March peak of $34.20. The decline highlights investor skepticism about whether the company can sustain its momentum and translate margin improvements into consistent earnings growth.
Management moved to reassure investors by reaffirming its long-term targets, including a fiscal 2027 adjusted EBITDA goal of $45 million to $50 million. The company also indicated it expects fiscal 2026 to deliver its strongest annual sales performance to date, suggesting the business fundamentals remain intact despite the quarterly stumble.
The disconnect between Lifeway's operational performance and its stock price reflects broader challenges in the probiotic market. While consumer demand for gut health products has expanded significantly, competition from larger food and beverage companies has intensified, putting pressure on smaller players to demonstrate consistent profitability and market share gains.
Analysts see significant upside potential, with a consensus target price of $35—roughly 69% above current levels. The company trades at 28 times trailing earnings and 29.9 times forward earnings, a premium multiple that investors may find difficult to justify absent evidence of accelerating growth.
Lifeway's balance sheet appears relatively healthy, with a profit margin of 5.5% and operating margin of 8.8%. The company has maintained positive returns on both assets (8.2%) and equity (14.5%), suggesting efficient capital deployment. However, with insider ownership at 64.3% and institutional ownership at just 32.7%, the stock remains lightly held by major asset managers, which can contribute to volatility.
The company's kefir-based products have established a loyal consumer base in the growing functional food market, where demand for probiotic-rich offerings continues to rise. Gross margin expansion of 140 basis points indicates the company is successfully managing costs despite supply chain pressures and competitive pricing dynamics.
Investors will be watching closely for signs that the fourth-quarter earnings miss was an anomaly rather than a trend. Management's bullish outlook for 2026 sales suggests confidence in the company's growth trajectory, but execution will be critical to rebuilding market confidence and pushing shares back toward their 52-week highs.
As the company works toward its 2027 EBITDA targets, the focus will likely shift to demonstrating operational efficiency, market share stability, and the ability to navigate an increasingly competitive landscape without sacrificing profitability.